Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM opened at $1.99 on Tuesday. The company has a market capitalization of $7.27 million, a price-to-earnings ratio of -0.52 and a beta of 0.92. The business’s 50-day moving average price is $1.85 and its two-hundred day moving average price is $1.88. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $3.14.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%. The firm had revenue of $2.20 million during the quarter.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP bought a new stake in Pulmatrix during the 1st quarter worth about $73,000. Mariner LLC bought a new stake in Pulmatrix during the fourth quarter worth about $97,000. Citadel Advisors LLC acquired a new position in Pulmatrix during the second quarter valued at approximately $141,000. Vanguard Group Inc. grew its stake in Pulmatrix by 62.9% in the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 13,548 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,300 shares during the last quarter. Institutional investors and hedge funds own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.